STOCK TITAN

Novavax Inc - NVAX STOCK NEWS

Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.

Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.

Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.

Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.

Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced a Phase 2b clinical trial revealing a 77% efficacy rate for its malaria vaccine candidate, R21, developed with the University of Oxford. This study, published in Preprints with The Lancet, involved 450 children in Burkina Faso and highlighted the well-tolerated nature of the vaccine. The Royalty agreement with the Serum Institute of India allows for the production of at least 200 million doses annually. A Phase 3 trial is now recruiting participants across Africa to assess the vaccine's safety and efficacy on a larger scale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced its participation in the Phase 2 Com-COV2 clinical trial led by the University of Oxford, evaluating the efficacy of mixed COVID-19 vaccine regimens. The trial includes 1,050 adults over 50, assessing responses to NVX-CoV2373 alongside other vaccines. The study aims to determine if combining different vaccines can safely enhance immune responses compared to standard regimens. NVX-CoV2373 has shown strong efficacy in previous trials and is designed for stable storage and distribution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
conferences covid-19
-
News
Rhea-AI Summary

On April 13, 2021, Novavax, Inc. (Nasdaq: NVAX) announced significant leadership changes, promoting Gale E. Smith to Senior VP of Discovery and Pre-Clinical Research, and appointing Troy Morgan as Senior VP and Chief Compliance Officer. Greg Covino will step down as CFO but remain as an executive adviser. Dr. Smith is recognized for his contributions to vaccine technology, while Mr. Morgan brings extensive compliance expertise. These changes come as Novavax progresses in the commercialization of its COVID-19 vaccine and seeks to enhance its operational compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
none
News
Rhea-AI Summary

On April 13, 2021, Novavax, Inc. (Nasdaq: NVAX) announced key leadership changes, promoting Gale E. Smith, Ph.D., to Senior VP and Chief Scientist, while appointing Troy Morgan as Senior VP and Chief Compliance Officer. Greg Covino will step down as CFO but remain as an executive adviser. Dr. Smith's contributions to Novavax's COVID-19 vaccine candidate and vaccine technology development were highlighted. Morgan brings extensive compliance experience, crucial for Novavax's commercialization strategy. These changes reflect the company's commitment to advancing vaccine solutions against serious infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
none
-
Rhea-AI Summary

Novavax (Nasdaq: NVAX), a biotechnology firm, will take part in a fireside chat at the Goldman Sachs virtual conference on April 13, 2021, from 2:30 to 3:20 p.m. ET. The discussion will focus on Novavax's COVID-19 vaccine candidate, NVX-CoV2373, and its implications for the current vaccine landscape. Vivek Shinde, M.D., M.P.H., Vice President of Clinical Development, will represent the company. This event is exclusive to Goldman Sachs clients, highlighting Novavax's ongoing efforts in developing innovative vaccines against serious infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
conferences
-
Rhea-AI Summary

Novavax has initiated crossover arms in its clinical trials for NVX-CoV2373, its COVID-19 vaccine candidate. This allows all participants in the South Africa and UK trials to receive active vaccine doses, ensuring long-term safety and efficacy monitoring. The PREVENT-19 trial in the US and Mexico plans a similar crossover. The trials include a Phase 2b study in South Africa and a pivotal Phase 3 in the UK, with initial data expected in Q2. NVX-CoV2373 boasts a 96.4% efficacy rate against the original virus strain and remains stable at 2°-8°C for distribution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
clinical trial covid-19
Rhea-AI Summary

On April 5, 2021, Novavax (Nasdaq: NVAX) announced that CEO Stanley C. Erck will participate in a panel discussion at the Longwood Healthcare Leaders 2021 Webconference on April 6, 2021. The discussion, titled Progress Towards Sustainable Vaccines for COVID-19, will focus on Novavax's COVID-19 vaccine candidate, NVX-CoV2373. The panel is scheduled for 7:30 – 8:00 a.m. EDT and will be moderated by Harvard's Michael Mina. Novavax is at the forefront of developing innovative vaccines to combat serious infectious diseases, including COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
conferences
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announces a collaboration with GSK and the UK Government to manufacture up to 60 million doses of its COVID-19 vaccine candidate, NVX-CoV2373, starting from May 2021. Under this agreement, GSK will utilize its Barnard Castle facility for 'fill and finish' operations. This partnership aims to bolster the UK's vaccine rollout as over 30 million doses have already been administered. The NVX-CoV2373 vaccine has shown promising efficacy in Phase 3 trials, and regulatory submission is anticipated in the second quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
covid-19
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced remarkable results from its COVID-19 vaccine, NVX-CoV2373, in pivotal trials. The final analysis of the U.K. Phase 3 trial demonstrated a 96.4% efficacy against the original strain and 89.7% overall efficacy, with 100% protection against severe disease. In South Africa, the Phase 2b trial revealed 55.4% efficacy among HIV-negative participants. Both studies confirmed the vaccine’s effectiveness against variant strains and showed it was well-tolerated. Novavax plans to submit data for regulatory authorization worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.07%
Tags
covid-19
Rhea-AI Summary

Novavax (Nasdaq: NVAX) announced its participation in a fireside chat at the H.C. Wainwright Virtual Global Life Sciences conference on March 9, 2021. The discussion will focus on Novavax's COVID-19 vaccine candidate, NVX-CoV2373, featuring Dr. Gregory M. Glenn and John Trizzino as speakers. The session will be available on-demand starting at 7:00 a.m. ET. A replay will also be accessible for 90 days on the company’s website.

Novavax specializes in creating next-generation vaccines to combat serious infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
conferences
Novavax Inc

Nasdaq:NVAX

NVAX Rankings

NVAX Stock Data

965.07M
146.70M
8.8%
60.18%
24.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
GAITHERSBURG